
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd is a promising biopharmaceutical company with a strong focus on monoclonal antibody therapies for viral infections, such as COVID-19 and RSV. Their lead product, PEMGARDA, has already received emergency use authorization and is expected to receive full approval in the near future, providing a strong revenue potential. The company's new antibody candidate, VYD2311, has shown promising results in clinical trials and has the potential to secure a significant portion of the market by 2030. However, the company may face competition and risks in the constantly evolving and competitive vaccine development industry.
Bears say
Invivyd is a biopharmaceutical company focused on monoclonal antibody therapies for viral diseases, with their lead product receiving emergency use authorization for COVID-19. However, the company's focus on infectious diseases and emerging variants leaves them vulnerable to changing market demands and potential competition. Additionally, with a relatively small pipeline of vaccine candidates, Invivyd's financial success heavily relies on the success of Pemgarada and its ability to secure partnerships or licensing agreements for future products. Without a diverse portfolio and limited financial resources, Invivyd may struggle to stay competitive in the highly dynamic and competitive biopharmaceutical industry.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares